Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1

Haruko Tashiro,1 Tim Sauer,1 Thomas Shum,1,6 Kathan Parikh,1 Maksim Mamonkin,1,3 Bilal Omer,1,2,7 Rayne H. Rouce,1,2,7 Premal Lulla,1,5 Cliona M. Rooney,1,2,3,4 Stephen Gottschalk,1,2,3 and Malcolm K. Brenner1

1Center for Cell and Gene Therapy, Texas Children’s Hospital, Houston Methodist Hospital and Baylor College of Medicine, Houston, TX 77030, USA; 2Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA; 3Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX 77030, USA; 4Department of Molecular Virology and Immunology, Baylor College of Medicine, Houston, TX 77030, USA; 5Section of Hematology/Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA; 6Interdepartmental Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, TX 77030, USA; 7Texas Children’s Cancer and Hematology Centers, Baylor College of Medicine, Houston, TX 77030, USA

The successful immunotherapy of acute myeloid leukemia (AML) has been hampered because most potential antigenic targets are shared with normal hematopoietic stem cells (HSCs), increasing the risk of sustained and severe hematopoietic toxicity following treatment. C-type lectin-like molecule 1 (CLL-1) is a membrane glycoprotein expressed by >80% of AML but is absent on normal HSCs. Here we describe the development and evaluation of CLL-1-specific chimeric antigen receptor T cells (CLL-1.CAR-Ts) and we demonstrate their specific activity against CLL-1+ AML cell lines as well as primary AML patient samples in vitro. CLL-1.CAR-Ts selectively reduced leukemic colony formation in primary AML patient peripheral blood mononuclear cells compared to control T cells. In a human xenograft mouse model, CLL-1.CAR-Ts mediated anti-leukemic activity against disseminated AML and significantly extended survival. By contrast, the colony formation of normal progenitor cells remained intact following CLL-1.CAR-T treatment. Although CLL-1.CAR-Ts are cytotoxic to mature normal myeloid cells, the selective sparing of normal hematopoietic progenitor cells should allow full myeloid recovery once CLL-1.CAR-T activity terminates. To enable elective ablation of the CAR-T, we therefore introduced the inducible caspase-9 suicide gene system and we show that exposure to the activating drug rapidly induced a controlled decrease of unwanted CLL-1.CAR-T activity against mature normal myeloid cells.

INTRODUCTION

Treatment for acute myeloid leukemia (AML) has advanced only modestly over the past 30 years. Although chemotherapy can induce complete remission, it is toxic and has a high rate of failure. Moreover, standard chemotherapy often fails to eliminate leukemic stem cells (LSCs)—a small population of cells that are quiescent, are resistant to chemotherapy, and are likely responsible for AML initiation and subsequent relapse.1 Allogeneic hematopoietic stem cell transplantation (HSCT) may benefit some patients but toxicities and failure rates still remain high, excluding many elderly patients with significant morbidities in whom the disease is most common. Therefore, there has been great interest in targeting AML by less toxic immunotherapies with activity against LSCs.

The striking success of CD19-specific chimeric antigen receptor T cell (CAR-T) therapies against acute lymphoblastic leukemia (ALL) has not yet been matched in AML.2–4 One major obstacle to targeting AML with CAR-Ts is that many myeloid antigens are expressed at similar levels on normal and malignant cells. Eliminating leukemic cells therefore may occur at the expense of normal myeloid tissue, including myeloid progenitor cells, resulting in an unacceptable “on target, off tumor” effect. Several preclinical studies have reported CARs targeting AML-associated antigens such as Lewis Y,5 CD33,6,7 CD44v6,8 CD123,7,9,10 and folate receptor β (FRβ).11,12 Among these, Lewis Y, CD33, and CD123 have been used clinically but sustained complete responses have not yet been reported.5,8,13 Toxicities toward normal hematopoietic progenitor cells (HPCs) associated with the CD33 and CD123 CAR-T cell treatments have also been of particular concern.

C-type lectin-like molecule 1 (CLL-1) may be an effective alternative target for AML with specificity against leukemic progenitor cells and their progeny, while sparing normal myeloid precursor cells.14,15 The antigen is a type II transmembrane protein and its expression is limited to myeloid lineage cells.16 CLL-1 is present on 85%–92% of AML of all French-American-British (FAB) classes (M0–M6).16–18 CLL-1 is also expressed on CD34+CD38− AML LSCs.15 When CD34+/CLL-1+ leukemic cells engraft in non-obese diabetic...
(NOD)/severe combined immunodeficiency (SCID) mice, they outgrow to CLL-1+ blasts, suggesting that these cells have the functional properties of LSCs. Additionally, CLL-1 is expressed on differentiated myeloid cells but not on normal hematopoietic stem cells (HSCs), indicating that a CLL-1-targeted therapy would spare these cells.

Here we generated CLL-1-specific CAR-Ts (CLL-1.CAR-Ts) and demonstrated selective killing of leukemic progenitor cells and their progeny. Although CLL-1.CAR-Ts killed mature normal myeloid cells, normal myeloid precursor cells were spared, judging by in vitro cord blood (CB) colony-forming assays. Since we also show that CLL-1.CAR-T activity can be electively terminated by inducible apoptosis following elimination of AML cells and LSCs, myeloid reconstitution in treated patients should occur via the unharmed normal precursor cells.

RESULTS

CLL-1 Is Expressed by AML Cell Lines and Primary AML Blasts

To validate CLL-1 as a target antigen for CAR-T cell therapy against AML, we first evaluated CLL-1 expression in AML cell lines and primary AML blasts. The chronic myeloid leukemia cell line K562 does not express CLL-1 (Figure S1A) and we used it as a negative control. Consistent with previous reports, CLL-1 was expressed by several AML cell lines at different intensities (Figure 1A). Next, we analyzed CLL-1 expression on peripheral blood samples from 19 patients with AML whose disease subtypes are summarized in Table 1. CLL-1 was measured in 95% of AML cases (18 of 19) with a range of positivity between 31.7% and 99.8% when gated on CD45dim/side scatter (SSC) populations enriched for AML blasts (Figures 1B and 1C). Relative CLL-1 mean fluorescence intensities (MFIs) (normalized to isotype control) are summarized in Figure 1D. We also detected CLL-1 expression on peripheral blood from six healthy donors. As previously reported, CLL-1 expression was restricted to myeloid cells (i.e., granulocytes, mature/precursor dendritic cells [DCs], and monocytes); T and B lymphocytes and natural killer (NK) cells did not express CLL-1 (Figures S1B and S1C).

Generation and Evaluation of CLL-1-Specific CAR-Ts

We utilized a CLL-1-specific single-chain fragment variable (scFv) to create a panel of CLL-1.CARs with various costimulatory domains consisting of a CLL-1 scFv fused with a CD8α stalk and transmembrane domains (Figure S2A). We used the CD3ζ signaling domain (CLL-1.ζ) alone or in combination with one or two complementary costimulatory endodomains: CD28 (CLL-1.28ζ) or 4-1BB (CLL-1.BBζ), CD28 and 4-1BB (CLL-1.28.BBζ), or CD28 and OX40 (CLL-1.28.OX40ζ). A truncated version of CLL-1.CAR (CLL-1.Dζ) was created by deleting intracellular signaling domains and was used as a control. To determine the functionally optimal construct, we compared the memory phenotype, cytokine production, and cytolytic ability of T cells expressing the five CLL-1.CARs. As summarized in Figures S3 and S4, the CLL-1.BBζ construct showed a trend of the greatest specific cytokine release and the most sustained cytolytic activity and was therefore used in all further studies.

CLL-1.BBζ CAR-Ts Produce Pro-inflammatory Cytokines in Response to CLL-1-Expressing Target Cells

We used a multiplex assay to evaluate the cytokine production of CLL-1.CAR-Ts. When compared with non-transduced activated

Figure 1. CLL-1 Is Expressed in Several AML Cell Lines and Primary AML

(A) Surface expression of CLL-1 on AML cell lines THP-1, HL60, MOLM13, Kasumi-3, and KG1a was determined by flow cytometry using CLL-1-AF647 antibody (clone: 50C1) (dark gray) and isotype IgG2ak antibody (light gray). (B–D) Primary patient AML blasts from a diverse range of disease subtypes express CLL-1 (n = 19; shown in Table 1). (B) CLL-1 expression levels vary among leukemias, as reviewed by gating on a SSCdim/CD45dim blast population using the same antibodies as in (A). (Left) One representative gating strategy of 19 AML patient samples. (Right) Data from three representative patients (patients 1, 7, and 16) are shown (right). (C) Combined data on the percentage of CLL-1-positive cells from primary AML (n = 19) and AML cell lines (n = 5). (D) Combined data on relative CLL-1 MFI to isotype MFI (CLL-1/isotype control) from primary AML (n = 19) and AML cell lines (n = 5). SSC, side scatter.
T cells (NT-ATCs) or CLL-1.Δ-Ts, CLL-1.BBζ CAR-Ts secreted significantly greater amounts of interferon (IFN)-γ, tumor necrosis factor (TNF)-α, interleukin (IL)-2, and granulocyte-macrophage colony-stimulating factor (GM-CSF) (Figure 2A) in response to the CLL-1-expressing AML cell line HL60. Background production of the cytokines by CLL-1.BBζ CAR-T was minimal and comparable to that of the NT-ATC and CLL-1.Δ-Ts controls. Moreover, CLL-1.BBζ CAR-Ts responded to a wide range of CLL-1-expressing target cells (Figure 2B, left) indicating that the CLL-1.CAR-T can target a broad span of antigen expression on AML blasts. The magnitude of IFN-γ production correlated with the relative CLL-1 MFI (normalized to isotype control) (Figure 2B, right; r(10) = 0.70, p < 0.01).

Antigen-dependent cytokine release was accompanied by proliferation. CLL-1.BBζ CAR-Ts were stained with CellTrace Violet and proliferation was measured by dilution (CellTrace Violet dilution) only when stimulated with CLL-1+ cell lines HL60 or THP-1, or the CLL-1-negative cell line K562. After 5 days of stimulation, CLL-1.BBζ CAR-Ts showed substantial proliferation (detected by CellTrace Violet dilution) only when stimulated with CLL-1+ cell lines HL60 or THP-1 (Figure 2C), indicating that the activation of CLL-1.CAR-Ts is CLL-1 specific. We also tested whether CLL-1.BBζ CAR-Ts could proliferate in response to primary AML samples. After stimulation with CLL-1-expressing primary AML samples (patients 1, 2, and 4), they showed robust proliferation (Figure 2F). CLL-1.Δ-Ts also showed low-level proliferation, likely due to alloreactivity.

**Table 1. Patient Characteristics**

<table>
<thead>
<tr>
<th>AML Sample ID</th>
<th>Age (Years)</th>
<th>Sex</th>
<th>Cytogenetics</th>
<th>CLL-1 Positivity</th>
<th>CLL-1 Relative MFI</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>12</td>
<td>M</td>
<td>46, XY</td>
<td>96.1</td>
<td>21.2</td>
</tr>
<tr>
<td>2</td>
<td>44</td>
<td>F</td>
<td>Inv(16)(p13.1q22)</td>
<td>69.1</td>
<td>12.8</td>
</tr>
<tr>
<td>3</td>
<td>67</td>
<td>M</td>
<td>47, XY, +21</td>
<td>86.3</td>
<td>17.0</td>
</tr>
<tr>
<td>4</td>
<td>80</td>
<td>M</td>
<td>46, XY</td>
<td>67.5</td>
<td>26.4</td>
</tr>
<tr>
<td>5</td>
<td>27</td>
<td>F</td>
<td>46, XX</td>
<td>31.7</td>
<td>7.1</td>
</tr>
<tr>
<td>6</td>
<td>78</td>
<td>M</td>
<td>46, XY, t(17)(q10)</td>
<td>53.0</td>
<td>6.7</td>
</tr>
<tr>
<td>7</td>
<td>76</td>
<td>M</td>
<td>46, XY</td>
<td>71.6</td>
<td>10.8</td>
</tr>
<tr>
<td>8</td>
<td>74</td>
<td>M</td>
<td>trisomy 8</td>
<td>45.4</td>
<td>6.8</td>
</tr>
<tr>
<td>9</td>
<td>53</td>
<td>M</td>
<td>t(15;17)(q24;q21)</td>
<td>99.8</td>
<td>21.0</td>
</tr>
<tr>
<td>10</td>
<td>16 months</td>
<td>M</td>
<td>trisomy 8, MLL-R</td>
<td>98.8</td>
<td>9.4</td>
</tr>
<tr>
<td>11</td>
<td>13</td>
<td>M</td>
<td>t(6;11), MLL-R</td>
<td>99.5</td>
<td>11.8</td>
</tr>
<tr>
<td>12</td>
<td>8</td>
<td>M</td>
<td>t(9;11), MLL-R</td>
<td>85.4</td>
<td>5.6</td>
</tr>
<tr>
<td>13</td>
<td>13</td>
<td>M</td>
<td>46, XY</td>
<td>65.9</td>
<td>9.0</td>
</tr>
<tr>
<td>14</td>
<td>15</td>
<td>M</td>
<td>unavailable</td>
<td>60.0</td>
<td>5.5</td>
</tr>
<tr>
<td>15</td>
<td>16</td>
<td>F</td>
<td>trisomy 8</td>
<td>92.5</td>
<td>20.8</td>
</tr>
<tr>
<td>16</td>
<td>14</td>
<td>M</td>
<td>t(8;21)</td>
<td>4.22</td>
<td>2.5</td>
</tr>
<tr>
<td>17</td>
<td>11</td>
<td>F</td>
<td>t(16;21)</td>
<td>52.6</td>
<td>3.6</td>
</tr>
<tr>
<td>18</td>
<td>84</td>
<td>M</td>
<td>46, XY</td>
<td>94.7</td>
<td>19.7</td>
</tr>
<tr>
<td>19</td>
<td>69</td>
<td>F</td>
<td>complex abnormalities, inv(16)(p13.1q22)</td>
<td>44.1</td>
<td>3.0</td>
</tr>
</tbody>
</table>

F, female; ID, identification number; M, male; MLL-R, MLL gene rearrangement.

**Figure 3A**: We used a luciferase-based cytotoxicity assay to verify the specific cytotoxicity of CLL-1.BBζ CAR-Ts. Compared to CLL-1.Δ-Ts, CLL-1.BBζ CAR-Ts exhibited significant cytotoxicity against HL60 cells, while the reactivity against a CLL-1-negative cell line (LAN1) was minimal (Figure 3A). We also assessed longer-term cytotoxicity against the CLL-1+ AML cell lines HL60 or THP-1 cells upon co-culture with CLL-1.BBζ CAR-Ts at an effector-to-target (E:T) ratio of 1:2 for 3 days. We observed a significant reduction in live tumor cells by flow at the end of culture with CLL-1.BBζ CAR-Ts compared to CLL-1.Δ-Ts, indicating robust and specific cytotoxicity of CAR-Ts against CLL-1+ targets (Figure 3B; HL60, p < 0.0001; THP-1, p < 0.0001).

Next, we tested whether CLL-1.BBζ CAR-Ts had anti-leukemic activity against primary AML samples. We co-cultured CLL-1.Δ-Ts or CLL-1.BBζ CAR-Ts with peripheral blood mononuclear cells (PBMCs) from four patients with AML at an E:T ratio of 1:1 in the absence of exogenous cytokines. Three days later, we enumerated CD34+ (AML) and CD3+ (CAR-T) cells. T cells expressing the CAR-T demonstrated potent cytotoxicity compared to CLL-1.Δ-Ts (patient 1: p = 0.0197, patient 2: p = 0.0083, patient 3: p = 0.0067, patient 4: p = 0.0418). Moreover, primary tumor cells induced expansion of CLL-1.BBζ CAR-Ts but not control CLL-1.Δ-Ts (patient 1, p < 0.0001; patient 2, p = 0.0267) (Figure 3C).

To confirm that CLL-1.BBζ CAR-Ts are cytotoxic against leukemic progenitor cells, we measured their ability to inhibit leukemic colony formation using T cells from three different healthy donors against leukemic cells from three patients with AML. In all combinations, leukemic colony formation was consistently and significantly inhibited upon incubation with CLL-1.BBζ CAR-Ts compared to CLL-1.Δ-Ts (Figure 3D). We conclude that CLL-1.CAR-Ts are cytotoxic against AML cell lines and primary AML cells.

**Figure 4A**: We used a human xenograft mouse model of AML in which NOD.Cg-Prkdc<sup>scid</sup> IL2rg<sup>−/−</sup> (NSG) mice were systemically engrafted with HL60-GFP+ cells (GFPfLuc). We used bioluminescent imaging (BLI) to monitor tumor growth. Control groups receiving CLL-1.Δ-Ts demonstrated rapid leukemia progression, with a median survival of < 40 days (Figures 4B–4D). By contrast, 8 of 10 mice receiving CLL-1.BBζ CAR-Ts showed a consistently lower leukemia burden associated with significantly improved survival (Figures 4B–4D).
The CLL-1 antigen is expressed by normal differentiated myeloid cells, including granulocytes, DCs, and monocytes (Figure S1C). We therefore assessed the cytotoxic activity of CLL-1.CAR-Ts against normal autologous CD14+ myeloid cells. CLL-1.BBz CAR-Ts were reactive against normal myeloid cells, leading to IFN-γ production (Figure 5A), proliferation (Figure 5B), and cytotoxicity (Figure 5C). Since CLL-1 is absent on HSCs and primitive myeloid precursors,19 however, these critical cell populations should be spared by CLL-1.CAR-Ts. As anticipated, co-culturing CLL-1.BBz CAR-Ts with CB samples containing HSCs and myeloid precursors at an E:T ratio of 10:1 did not inhibit myeloid and erythroid colony formation (Figure 5D), indicating that the toxicity of CLL-1.CAR-Ts should be confined to mature myeloid cells and that myeloid progenitor cells should be spared. We determined whether the extent of toxicity to mature myeloid cells could be controlled by terminating the activity of CLL-1.CAR-Ts after leukemia elimination, thereby allowing post-treatment myeloid reconstitution via the unharmed normal precursor cells. We therefore introduced a clinically validated safety switch based on inducible caspase 9 (iC9).23–25 We double-transduced T cells with both CLL-1.BBz CAR and ΔCD34-iC9 constructs (iC9/CLL-1.BBz) and selected...
DISCUSSION

We aimed to develop CAR-Ts that would target AML blasts and LSCs while sparing normal HSCs. We show that CAR-Ts specific for CLL-1 exhibit potent cytokine production, proliferation, and cytotoxicity against CLL-1-expressing AML cell lines and primary AML samples without disrupting normal HSCs. CLL-1.CAR-Ts also had anti-leukemic activity against human xenografts. Although CLL-1 is also expressed on normal differentiated myeloid cells and CLL-1.CAR-Ts are cytolytic against autologous CD14+ monocytes, normal precursor cells are unharmed by CLL-1.CAR-T treatment in colony-forming assays. Hence, deletion of the CAR-T cells either by natural attrition or exhaustion may allow full recovery from spared precursor cells. Alternatively, the iC-9 suicide gene system may allow for rapid and elective elimination of iC9/CLL-1.CAR-Ts in vitro and in vivo.23–25

Multiple immunotherapeutic approaches against AML have been explored, including vaccination, monoclonal antibodies (with or without toxins, cytotoxic small molecules, or radionuclides), and adoptive cell therapies, with only modest benefit shown thus far.26

Figure 3. iC9-Expressing Cells Using CD34 MACS Beads. iC9/CLL-1.BBz CAR-Ts killed HL60 target cells as effectively as T cells expressing CLL-1.BBz alone (Figure S6A). Activation with the chemical inducer of dimerization (CID) dimerizer triggered apoptosis in > 90% of iC9/CLL-1.BBz CAR-Ts (Figure 6A) and reversed the cytotoxic activity of iC9/CLL-1.BBz CAR-Ts against CLL-1-expressing CD14+ autologous cells (Figure 6B). We also controlled iC9/CLL-1.BBz CAR-T expansion in vivo using wild-type (WT)-HL60-bearing mice treated with 2 × 10^6 iC9/CLL-1.BBz expressing GFPffluc. We tested low and high doses of CID to model efforts to produce titratable (limited and then more complete) control of potential toxicities. We administered the low-dose dimerizer (3 μg/mouse) to mice on days 14 and 16, which transiently decreased T cell signals and was followed by subsequent rebound. We administered CID (50 μg/mouse) on days 23, 25, and 27, which further decreased the T cell signal (Figure S6B).

Figure 4. CLL-1.CAR-T Inhibits HL60 Engraftment in Xenograft Models
(A) Schematic outline of the HL60 xenograft model. NSG mice were sub-lethally irradiated (200 cGy) on day –2 and then injected via the tail vein with 50,000 HL60-GFPffluc on day –1. Mice received 0.6 × 10^9 CLL-1.D-T or CLL-1.BBz CAR-Ts and were followed with serial bioluminescent imaging (BLI). (B) Delayed leukemia engraftment was observed only in xenograft mice treated with CLL-1.BBz CAR-T. (C) Summary BLI data from three independent experiments. (D) Survival analysis of HL60 xenograft mice revealed a survival advantage for CLL-1.BBz CAR-T-treated mice compared to CLL-1.D-T-treated mice or untreated mice. ***p < 0.001, i.v., intravenous.

Figure 5. iC9-Expressing Cells Using CD34 MACS Beads. iC9/CLL-1.BBz CAR-Ts killed HL60 target cells as effectively as T cells expressing CLL-1.BBz alone (Figure S6A). Activation with the chemical inducer of dimerization (CID) dimerizer triggered apoptosis in > 90% of iC9/CLL-1.BBz CAR-Ts (Figure 6A) and reversed the cytotoxic activity of iC9/CLL-1.BBz CAR-Ts against CLL-1-expressing CD14+ autologous cells (Figure 6B). We also controlled iC9/CLL-1.BBz CAR-T expansion in vivo using wild-type (WT)-HL60-bearing mice treated with 2 × 10^6 iC9/CLL-1.BBz expressing GFPffluc. We tested low and high doses of CID to model efforts to produce titratable (limited and then more complete) control of potential toxicities. We administered the low-dose dimerizer (3 μg/mouse) to mice on days 14 and 16, which transiently decreased T cell signals and was followed by subsequent rebound. We administered CID (50 μg/mouse) on days 23, 25, and 27, which further decreased the T cell signal (Figure S6B).
The remarkable success of CAR-T cell therapy for B cell malignancies has obvious implications for the treatment of AML but, at a minimum, requires identification of AML-specific target(s) that can be detected by a single-chain antibody and are broadly expressed on malignant cells but not normal precursor cells. Such a CAR-T cell therapy would allow disease control without the need to rescue the patient from marrow aplasia with an allogeneic stem cell transplant. We chose to target CLL-1 with CAR-T for several reasons. First, CLL-1 is expressed by many AML subtypes. In our cohort, CLL-1 was expressed in 95% of AML blasts, with a range of 31.7%–99.8% positivity in primary AML blasts, which is similar to previous reports. Equally importantly, CLL-1 is not expressed by normal HSCs; when we cultured mononuclear cells from CB with CLL-1.CAR-Ts for 5 hr at an E:T ratio of 10:1 and then plated in semisolid methylcellulose progenitor culture for 14 days and scored for the presence of burst-forming unit erythroid (BFU-E) and granulocyte-macrophage colony-forming units (GM-CFU). Total colony numbers are shown. CLL-1.CAR-T was used as a negative control. Data represent the mean ± SD of three independent experiments performed in duplicate. **p < 0.0001. BBz, CLL-1.BBz-CAR-T; delta, CLL-1.D-T; n.s., not significant. A major drawback of targeting CLL-1 is that this antigen is also variably expressed in mature myeloid cells. However, as normal progenitor cells are not targeted by CLL-1.CAR-Ts, the decline or active elimination of this effector population after therapy should allow mature myeloid cell regeneration. To facilitate T cell ablation, we introduced the iC9 suicide gene system into the CLL-1.CAR-T. The iC9-transduced activated T cells or CAR-Ts can be rapidly and effectively eliminated by administration of the activating dimerizer drug (CID) in vitro as well as in vivo in a range of pre-clinical models and in the clinic. Alternatives to elective elimination of a CLL-1.CAR-T by a suicide system include the use of transient expression or small-molecule inducible systems; however, these approaches have yet to be functionally validated in the clinic. AML is generally considered as a stem cell disease; since LSCs express the CAR-T we describe could in principle eradicate the disease. Our ultimate goal is to provide a CAR for AML that does not require HSCT. Although CLL-1 is absent on HSCs, and no effect of CLL-1 CAR T cells was observed in the short-term colony-forming assay, until we have direct clinical evidence of the selective sparing of human precursor cells in vivo, initial clinical studies will likely use these CAR-T cells to induce remission and act as a bridge to stem cell transplantation. If progenitor cells are indeed spared in these
initial studies, we propose that iC9-CLL-1.CAR-Ts may be useful for induction failure or chemotherapy refractory relapses.

Targeting a single antigen, however, may not be sufficient for any CAR-T cell therapy. Relapse from epitope-loss variants or lineage switch after CD19 CAR-T cell therapy against ALL have already been reported, and there are numerous other examples of tumor-antigen editing in response to immunotherapy. Moreover, activity against sub-populations of tumor cells expressing low levels of the target antigen will likely be suboptimal—a problem shared by all CAR-T cell approaches, even the successful CD19 CAR. Both of these limitations may require targeting of two or more tumor antigens, either by dual CARs or by adopting a tandem CAR exodomain that contains two differently targeted scFvs in a single CAR. Similar combination systems to attack CLL-1 and other AML-LSC antigens could be a practical method to broaden the range of targetable leukemias to include those that dimly express CLL-1 but highly express a second target antigen. As a second target for dual or tandem CAR, other LSC antigens, such as Tim-3, CD96, and CD123, may broaden the susceptible cell population. To avoid mature myeloid cell killing, it may be possible to use a split CAR strategy with the co-stimulatory CAR targeting an antigen that is expressed by AML blasts or LSCs but not mature myeloid cells. Conversely, combination of the CLL-1 CAR with an inhibitory CAR (iCAR) may also be possible, using an antigen that is expressed by mature myeloid cells but not by AML blasts or LSCs.

In conclusion, we have generated CLL-1.CAR-Ts that specifically target AML blasts and progenitor cells while sparing normal HSCs, and whose activity can be electively terminated by a suicide system.

MATERIALS AND METHODS

CAR and iC9 Construction

To generate SFG.CLL-1z-internal ribosome entry site (IRES)-ΔCD19, we synthesized (Bio Basic) cDNA containing the VH and VL chains from the single-chain variable regions (scFv) of the CLL-1 monoclonal antibody. We then PCR amplified this fragment and used In-Fusion Cloning (Takara/Clontech) to insert the CLL-1.z CAR fragment into a linearized SFG vector that contained IRES and a truncated CD19 construct downstream of the ligation site. These PCR products were cloned into a backbone gamma retrovirus SFG vector 14g2a.zeta using XhoI and MluI sites. CLL-1.D, CLL-1.CD28z, CLL-1.41BBz, CLL-1.CD28.41BBz, and CLL-1.CD28.OX40z were also created by In-Fusion cloning. The construction of the iC9 suicide gene was previously reported. CD34 was used as a selectable marker of iC9 transduced cells.
Retroviral Vector Production and T Cell Transduction

Retroviral vector production and T cell transduction were performed largely as previously described, with substitution of 10 ng/mL IL-7 (Peprotech) and 5 ng/mL IL-15 (Peprotech) for IL-2. T cells were expanded in complete medium (CM) (45% RPMI 1640; HyClone), 45% Click’s media ( Irvine Scientific), 2 mM L-glutamine (Gibco), and 10% fetal bovine serum (FBS) (HyClone). IL-7 and IL-15 were added to the culture during T cell expansion.

Cell Lines

We obtained the cell lines THP-1, HL60, MOLM13, Kasumi-3, KG1a, K562, LAN1 and 293T from ATCC. We maintained HL60, MOLM13, KG1a, and 293T in Iscove’s modified Dulbecco’s medium (IMDM; Gibco) and THP-1, Kasumi-3, K562, and LAN1 in RPMI. Media were supplemented with 2 mM L-glutamine, 10% or 20% FBS according to the manufacturer’s recommendations, as well as 1% penicillin-streptomycin (Invitrogen). Cells were incubated in a humidified atmosphere containing 5% CO₂ at 37°C. All cell lines were routinely tested for mycoplasma using the MycoAlert detection kit (Lonza). We transduced HL60 and LAN1 with a gamma retroviral vector encoding enhanced GFP fluorescent reporter.

Samples from Healthy Donors and Patients with Leukemia

We obtained PBMCs from healthy donors and patients with AML who gave written informed consent to be entered on protocols approved by the Baylor College of Medicine Institutional Review Board, in accordance with the Declaration of Helsinki.

CD14⁺ monocytes were isolated from PBMCs with CD14 magnetic beads according to the manufacturer’s instruction (Miltenyi Biotech). We obtained de-identified cord blood units from the MD Anderson Cord Blood Bank (University of Texas, Houston).

Flow Cytometry

Fluorochrome conjugated isotype controls, anti-human CD45, CD4, CD8, CD3, CD45RA, CD33, CD34, CD19, CCR7, CD70, PD-L1, CD80, CD86, and CD40L were purchased from BD Biosciences, Beckman Coulter, Life Technologies, or Biolegend. CLL-1, IgG2ak, and CD45RO were obtained from BD Pharmingen. AF647-conjugated goat anti-mouse IgG antibody (Fabs) were purchased from Jackson Immunoresearch. For primary AML samples, the CD45dim/SSClow populations were gated as the AML blast population. We acquired flow cytometric data by Gallios (Beckman Coulter) or BD FACS Canto II (BD Biosciences) and analyzed it using FlowJo (version 10; Tree Star).

Cytokine Release Assays

We cultured CAR-T cells (1 × 10⁵) with or without 1 × 10⁵ target cells in 200 μL CM. After 24 hr, supernatants were collected and analyzed directly or frozen at −80°C. We analyzed supernatants for the production of IFN-γ and IL-2 using the enzyme-linked immunosorbent assay (ELISA) (R&D Systems). We analyzed samples using the Milliplex kit according to the manufacturer’s instructions (Millipore).

Cytotoxicity Assay

We measured cytotoxicity against target cells using in vitro luciferase assays as previously described. Briefly, CLL-1⁺ HL60-GFPfluc cells or CLL-1 LAN1 GFPfluc cells were plated in 96-well black plates at 20,000 cells/well. T cells were added at multiple E:T ratios. After 5 hr of co-culture, D-luciferin (PerkinElmer) was added to each well and luminescence was quantified by a plate reader (Infinite M200; Tecan). The number of viable HL60-GFPfluc cells in each well was calculated based on a standard curve generated from serial dilutions of the target cells. We calculated T cell cytotoxicity using the following formula: percent cytotoxicity = (cell number in control well − cell number in assay well) × 100/cell number in control well (target cells alone). Cytotoxicity of CLL-1.CAR-Ts against autologous CD14⁺ monocytes was assessed by standard ⁵¹Cr release assays as previously described. For evaluation of iC9/CLL-1.CAR-T activity, we used a fixed E:T ratio (10:1) and added 1 μM or 10 μM of the CID (B/B homodimerizer, catalog no. 635038) from Clontech. After overnight incubation with CID, we added ⁵¹Cr-labeled autologous CD14⁺ target cells to the effector population and measured isotope release after 5 hr of incubation. Target cells were incubated in medium alone or in 1% Triton X-100 (Sigma-Aldrich) to determine spontaneous and maximum ⁵¹Cr release. Specific release was calculated as follows: percent-specific release = (test counts − spontaneous counts)/(maximum counts − spontaneous counts) × 100%.

Co-culture Assay

Transduced or non-transduced T cells (1 × 10⁵/well) were co-cultured with tumor cell lines (2 × 10⁵/well) at an E:T ratio of 1:2 or with PBMCs from primary AML (1 × 10⁵/well) at an E:T ratio of 1:1 in 48-well plates, in the absence of exogenous cytokines. For HL60-GFPfluc co-culture, cells were harvested and stained for CD3 after 3 days. We identified tumor cells by GFP expression. For serial co-culture assays, CD3⁺ T cells were collected every 3 days and counted by flow cytometry using CountBright beads (Thermo Fisher Scientific). We then replated and rechallenged T cells with fresh HL60-GFPfluc cells at the same E:T ratio. For THP-1 co-cultures, cells were harvested and stained for CD3 and CD33 to detect THP-1. For co-cultures of primary AML samples, cells were harvested and stained for CD3 and CD34 to differentiate between T cells and AML blasts. After assigning dead cells by measuring the population positive for 7-amino actinomycin D (7-AAD) (Thermo Fisher Scientific), residual tumor cells and T cells in cultures were enumerated by fluorescence-activated cell sorting (FACS) using CountBright beads.

Proliferation Assay

T cells were washed and resuspended at 1 × 10⁶/mL in CM. CellTrace Violet (Thermo Fisher Scientific) was added at 5 μM to T cells. T cells were incubated at 37°C for 20 min and washed. T cells were plated at 0.5 × 10⁶/well in 24-well plates with or without 0.5 × 10⁶/well stimulator cells.

Colony-Forming Assay with Leukemic or Normal Hematopoietic Progenitors

Mononuclear cells from the CB of healthy donors or PBMCs from patients with AML were co-incubated with CLL-1.BB⁺ CAR-Ts or
Sciences). We injected 0.6 \times 10^6 CLL-1 CAR-Ts at an E:T ratio of 10:1 for 5 hr and then plated in duplicate in methylcellulose-based medium supplemented with recombinant cytokines (MethoCult H4434 Classic; STEMCELL Technologies) as previously described.\(^4\) After 12–14 days of culture, we scored granulocyte-macrophage CFU and erythroid burst-forming unit erythroid (BFU) or leukemic colonies using an inverted microscope.

**Xenograft Model of AML and BLI**

NSG mice were purchased from the Jackson Laboratory and maintained at the Baylor College of Medicine Animal Facility. We sublethally irradiated (200 cGy) NSG mice (6–10 weeks of age) and injected them with 50,000 HL60-GFPffluc cells via their tail vein. Leukemia burden was monitored by BLI (in photons/s/cm²/steradian [sr]) using the Xenogen in vivo imaging system (IVIS) (Caliper Life Sciences). We injected 0.6 × 10^6 CLL-1.CAR-Ts or control CAR-Ts (CLL-1.Δ) on day 1 after tumor injection. All procedures complied with the requirements of the Institutional Animal Care and Usage Committee of Baylor College of Medicine. For the in vivo iC9/CLL-1.BB experiment, we injected NSG mice with 50,000 WT-HL60 cells via their tail vein day 1 after sublethal irradiation (200 cGy). We then injected 2 × 10^6 iC9/CLL-1.BB CAR-Ts labeled with GFPffluc on day 7 after tumor injection. T cell signals were monitored by BLI (in photons/s/cm²/sr). Mice were treated with either CID or vehicle on days 14, 16, 23, 25, and 27 after T cell injection. Mice in the CID group were given 3 μg CID on days 14 and 16 and then subsequently 50 μg CID on days 23, 25, and 27.

**In Vitro Apoptosis Study**

We incubated T cells in the presence of 10 nM CID for 24 hr. The cells were then harvested and stained with annexin V-allophycocyanin and 7-AAD. Flow cytometric data were acquired by Gallios (Beckman Coulter) and analyzed using FlowJo (version 10; Tree Star).

**Statistical Analysis**

We used GraphPad Prism 5 software (GraphPad Software) for statistical analysis and data are presented as means ± SE. For comparisons between two groups, we used the two-tailed Student’s t test. We compared three or more groups using one-way ANOVA with Bonferroni’s post-test. For the mouse experiments, we analyzed survival from the time of T cell injection by constructing Kaplan-Meier curves and using log-rank (Mantel-Cox) tests.

**SUPPLEMENTAL INFORMATION**

Supplemental Information includes Supplemental Materials and Methods and six figures and can be found with this article online at [http://dx.doi.org/10.1016/j.ymthe.2017.05.024](http://dx.doi.org/10.1016/j.ymthe.2017.05.024).

**AUTHOR CONTRIBUTIONS**

H.T. designed and performed the research, analyzed the data, and wrote the manuscript; T. Shum designed and performed the research, analyzed the data, and edited the manuscript; T. Sauer. designed and performed the research; K.P. performed the research; M.M. designed the research and edited the manuscript; B.O. designed the research; R.H.R. and P.L. provided primary AML samples and collected patients’ data; C.M.R. and S.G. designed the research and analyzed the data; and M.K.B. directed the study, designed the research, and worked with the authors to develop the final version of the manuscript.

**CONFLICTS OF INTEREST**

The authors declare no conflict of interest.

**ACKNOWLEDGMENTS**

The authors thank Dr. Caroline Arber for helpful discussion and technical support with the colony-forming assay, the Texas Children’s Cancer and Hematology Centers Flow Cytometry Core for technical support with cell sorting, and Catherine Gillespie for critical review of the manuscript. This study was supported in part by grants from the National Cancer Institute (NCI) (P01CA094237 and NCI Cancer Center support P30CA125123), the Leukemia Lymphoma Society (6483-16), and the Cancer Prevention Research Institute of Texas (CPRIT) (RP160693). T. Shum is supported by NIH/NHBLI (T32HL092332), NIH/NIDDK (T32DK060445), and, in part, by the Howard Hughes Medical Institute Med into Grad Initiative. P.L. is supported by a Leukemia Texas grant and an American Society for Blood and Marrow Transplantation (ASBMT) Young Investigator Award.

**REFERENCES**


